Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
Masonic Cancer Center, University of Minnesota
Study ID
NCT00869323
Phase
PHASE2
Status
Terminated

Conditions

  • Lymphoproliferative Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
    375 mg/m\^2 intravenously on Days 1,8, 15 and 22
  • bortezomib — DRUG
    1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22

Study Details

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with post-transplant lymphoproliferative disorders.

Key Dates

Start date
Mar 31, 2009
Status verified
Dec 2017
Primary completion
Mar 31, 2013
Completion
Dec 31, 2016

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treated Patients
    This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).

Primary Outcome Measure

Number of Patients With Overall (Complete and Partial) Response Rates [ Time Frame: Day 1 to 2 Years Post Treatment ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Minnesota Medical Center - FairviewMinneapolisMinnesota55455-
Washington University School of Medicine - Oncology DivisionSt LouisMissouri63110-

Find similar trials in Minneapolis, MN

By research site
University of Minnesota Medical Center - Fairview· Minneapolis, MNWashington University School of Medicine - Oncology Division· St Louis, MO

Related Studies